Memantina Normon

Memantine Hydrochloride, the active ingredient in Memantina Normon, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults, helping to manage cognitive decline associated with the condition.

GNH USA supplies Memantina Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory documentation and consistent product quality to meet global healthcare needs and ensuring timely delivery across regions.

Memantina Normon (memantine hydrochloride) acts on the glutamatergic system and is used in dementia care.

Alzheimer's disease: improves cognition and functional abilities in patients with moderate to severe disease.

Memantina Normon may cause a range of adverse reactions.

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel motility, manageable with diet or laxatives. - Confusion: occasional disorientation, more frequent in early treatment. - Hypertension: modest increase in blood pressure in some patients.

Serious or Rare Side Effects: - Seizures: rare but may occur, requiring immediate medical attention. - Cardiac arrhythmia: abnormal heart rhythms reported in isolated cases. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or hepatitis. - Suicidal ideation: emergent thoughts of self‑harm, necessitating prompt evaluation.

When prescribing Memantina Normon, clinicians should consider several safety aspects.

Renal impairment: dose adjustment may be required in patients with reduced kidney function. Hepatic disease: monitor liver function tests periodically. History of seizures: use with caution and observe for neurologic changes. Concurrent CNS depressants: may enhance dizziness or sedation. Pregnancy and lactation: safety not established; weigh potential benefits against risks. Store below 25°C: keep in the original pack, protect from moisture.

Memantina Normon can interact with other medicines; awareness of the interaction level guides management.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive effects on NMDA blockade can precipitate severe CNS depression. - Other NMDA antagonists: concurrent use may lead to excessive inhibition of glutamate signaling.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits of memantine. - CNS depressants (e.g., benzodiazepines): can heighten dizziness or sedation. - Diuretics: may alter plasma concentrations of memantine, requiring monitoring.